Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EN+ Group IPJSC Board/Management Information 2020

Apr 14, 2020

6440_mang_2020-04-14_258d426e-b7f1-4a6e-9118-ea2e4cef4776.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 4681J

EN+ Group Intnl PJSC

14 April 2020

EN+ GROUP ANNOUNCES THE DEATH OF A DIRECTOR

14 April 2020 - EN+ GROUP IPJSC (the "Company" or "En+ Group") (LSE: ENPL; MOEX: ENPL; MOEX: ENPG), announces with deep regret that Dr Igor Lojevsky, independent non-executive director of the Company, died on 12 April 2020 after a short illness. The Board extends its deepest condolences and sympathies to Dr Lojevsky's family and would like to take this opportunity to express its gratitude for his significant contribution to the Company.

A new independent non-executive director will be appointed to the EN+ Group Board in due course.

Lord Barker, Executive Chairman of En+ Group said:

"We are all terribly shocked by this tragic news.  Dr Igor Lojevsky was a great colleague. He was wise, thoughtful and a much valued independent member of our new board. Although he had only served for just over a year with the En+ Group, he had already made a distinct and important contribution, drawing on his sectoral experience gained at the World Bank and his many years as a distinguished  and senior investment banker. He will be sorely missed by all of us."

For further information, please contact:

For media: For investors:
Tel: +7 495 642 79 37

Email: [email protected]
Tel: +7 (495) 642 7937

Email: [email protected]
Hudson Sandler LLP

Andrew Leach

Tel: +44 (0) 20 7796 4133

Email: [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BOASFWFUDESSESL